Last reviewed · How we verify
ATI-5923
ATI-5923 is a selective inhibitor of phosphodiesterase 9 (PDE9) that increases cyclic GMP signaling in the central nervous system.
ATI-5923 is a selective inhibitor of phosphodiesterase 9 (PDE9) that increases cyclic GMP signaling in the central nervous system. Used for Cognitive impairment associated with schizophrenia, Alzheimer's disease.
At a glance
| Generic name | ATI-5923 |
|---|---|
| Sponsor | ARYx Therapeutics |
| Drug class | Phosphodiesterase 9 (PDE9) inhibitor |
| Target | PDE9 |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting PDE9, ATI-5923 prevents the breakdown of cyclic GMP, leading to enhanced cGMP-dependent signaling pathways. This mechanism is thought to improve cognitive function and neuroplasticity. The drug is being developed for neurodegenerative and cognitive disorders where PDE9 inhibition may provide therapeutic benefit.
Approved indications
- Cognitive impairment associated with schizophrenia
- Alzheimer's disease
Common side effects
- Headache
- Nausea
- Dizziness
Key clinical trials
- An Ascending, Multiple-Dose, Safety and Tolerability Study of Tecarfarin in Healthy Chinese Volunteers (PHASE1)
- A Study to Evaluate the Safety and Tolerability of Tecarfarin in Healthy Chinese Volunteers (PHASE1)
- Tecarfarin Anti-Coagulation Trial (TACT) (PHASE3)
- Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation (PHASE2, PHASE3)
- Study of a New Anticoagulant Drug in Patients With Atrial Fibrillation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ATI-5923 CI brief — competitive landscape report
- ATI-5923 updates RSS · CI watch RSS
- ARYx Therapeutics portfolio CI